IBJNews

Endocyte, Purdue develop prostate cancer treatment device

Back to TopCommentsE-mailPrintBookmark and Share
On The Beat Industry News In Brief

The man whose research launched West Lafayette-based Endocyte Inc. thinks he has a new innovation to treat prostate cancer.

Purdue University researcher Philip Low, also the chief science officer for Endocyte, has developed a prostate cancer “homing device” to help anti-cancer agents specifically target prostate cancer tumors. The device is a molecule synthesized by Low and his research team, which finds and penetrates prostate cancer cells.

Low

Low’s researchers have figured out how to attach anti-cancer drugs to the molecule or imaging agents that could help doctors target the tumors with radiation or surgery.

Better targeting of cancer therapy cuts down on severe side effects of traditional chemotherapy and radiation.

Endocyte targets other kinds of cancers by attaching drugs to folate molecules, which bind speedily to many cancer cells, but not to prostate cancers. Endoycte is funding Low’s latest round of research and will help pay for a clinical trial expected to start this fall at Indiana University Hospital in Indianapolis.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT